HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy

摘要

The ideal endpoint of hepatitis B virus (HBV) antiviral therapy is HBsAg loss, a difficult goal to obtain, especially in HBeAg negative patients. Herein, we report the results obtained by the addition of peg-interferon alpha-2a to a long-lasting nucleos(t)ide analogue therapy in a HBeAg negative, genotype D patient with steadily HBV-DNA negative/HBsAg positive values. In 2002, our Caucasian 44-year-old male patient received lamivudine and, 4 years later, added adefovir because of a virological breakthrough. In 2011, considering his young age, liver stiffness (4.3 kPa) and HBsAg levels (3533 IU/mL), we added Peg-interferon alpha-2a for six months (3 in combination with nucleos(t) ide analogues followed by 3 mo of Peg-interferon alpha-2a monotherapy). A decrease of HBsAg levels was observed after 1 mo (1.21 log) of Peg-interferon and 3 mo (1.88 log) after the discontinuation of all drugs. Later, a complete clearance of HBsAg was obtained with steadily undetectable HBV-DNA serum levels (< 9 IU/mL). HBsAg clearance by the addition of a short course of Peg-interferon alpha-2a represents an important result with clinical and pharmacoeconomic implications, considering that nucleos(t) ide analogues therapy in HBeAg negative chronic hepatitis B patients is considered a long-lasting/life-long treatment. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.